Conference Dates: Oct 26-28, 2009
San Francisco, CA[edit Location]
The ONLY U.S. event where you can have face-to-face dialogue with THE key players from China and India.
Hear case studies on:
* The impact of China’s health care reform
* New models in R&D, partnering and commercial models – DIRECTLY from major players who are actually implementing them!
* U.S. FDA’s strategy in Asia
* China health care reform – THE elephant in the room.
Hear all this in the U.S. – you don’t have to blow your travel budget flying to China and India. Asia leaders are coming here!
From Discovery to Clinical Trials to Market
As pharma looks to broaden its capabilities beyond its four walls and spread the risk and rewards of drug development, companies are looking east to the multi-billion dollar Asian market, especially emerging markets like China and India. Already many BioPharma companies are taking advantage of Asia’s scientific talent pool and large patient base to outsource R&D and clinical trials, and to develop unique alliances with local companies and universities to speed up drug development. With the global economic crisis upon us, and major pharma industry challenges like the approaching patent cliff, these R&D trends are likely to accelerate in coming years.
But speeding up development is just one reason multinationals want to build a presence in Asia. The other reason: emerging markets like China and India are the fastest growing markets for pharmaceuticals, with some experts forecasting growth of 14-15 percent in 2009, compared to 1-2 percent growth in the U.S. Yet regulatory, reimbursement and commercial challenges in these markets are considerable, and major changes are on the horizon, including China health care reform and the move toward a central India regulatory authority modeled after U.S. FDA.
PharmAsia News In light of these tremendous opportunities and challenges, Windhover conferences, sponsors of the blockbuster Pharmaceutical Strategic Alliances (PSA), and PharmAsia News – which leverages the editorial excellence of “The Pink Sheet” to provide
regulatory, legal and financial analysis of developments in China, India and The Pacific Rim – will gather the industry’s most senior leaders focusing on Asia and emerging markets to share best practice case studies; successful regulatory, reimbursement and commercial strategies; and strategic partnerships from discovery to clinical trials.
PharmAsia Summit is THE most strategic level meeting where senior level biotech and pharma executives share real-life case studies on how they are building a presence in Asia – from drug development to market. PharmAsia Summit will gather the industry’s most senior leaders to share best practice case studies, successful business models and strategic partnerships from discovery to clinical trials.
Join us for three days of interactive discussions, case studies and panels, and capitalize on Asia’s booming pharmaceutical market.
BEYOND THE BASICS! PharmAsia Summit is the only event featuring marquee level speakers and topics by the powerhouse editorial team from IN VIVO, START-UP, “THE PINK SHEET” and PHARMASIA NEWS. Discussions include:
* Heads of China R & D Roundtable: A Look at Different Models for Approaching Innovation in China
* China’s Changing Regulatory Landscape: The future of Chinese Healthcare Reform and What it Means for both Multinational and Chinese Companies
* Regulators Up Close: What can We Expect from Market Regulators in Asia?
* Indian Perspective on Globalization
* Partnering For Success In Emerging Markets: How Strategic Partnerships and M & A have Changed the Face of R & D in Asia
* Investment Outlook For Asia: VC Perspectives on their Best Bets
* Tips for Success: Working and Partnering with a CRO in Asia
* Building a Sales and Commercial Presence in China: How Do You Maximize Market Opportunities?
* Overcoming Intellectual Property Issues in Asia
* How to Conduct U.S. FDA Inspections in China
[edit description]Click here to register.[edit ]